Skip to main content

Table 3 Persistence breakdown by symptoms, adverse events, drug use, knowledge of family members about Wilson disease (WD) and position towards treatment

From: Persistence with treatment for Wilson disease: a retrospective study

Description

Persistent

Non-persistent

P value for persistent vs. non-persistent

Symptoms, n (%)

 Hepatic (n = 79)

57 (45.2)

22 (50.0)

0.59

 Neurological (n = 91)

69 (54.8)

22 (50.0)

 

Gender, n (%)

 Male (n = 77)

53 (42.1)

24 (54.5)

0.15

 Female (n = 93)

73 (57.9)

20 (45.5)

 

Adverse events, n (%)

 Yes (n = 61)

43 (34.1)

18 (40.9)

0.42

 No (n = 109)

83 (65.9)

26 (59.1)

 

Drug used, n (%)

 D-penicillamine (n = 76)

57 (45.2)

19 (43.2)

0.81

 Zinc sulphate (n = 94)

69 (54.8)

25 (56.8)

 

Treatment duration, mean ± SD, years

11.7 ± 3.2

11.6 ± 3.0

0.81

Educational level, n (%)

 Vocational education

29 (23.0)

11 (25.0)

 

 Upper secondary/post secondary

51 (40.5)

27 (61.4)

0.01

 Higher education

46 (36.5)

6 (13.6)

 

Family knowledge about WD, n (%)

 Minimal

4 (3.2)

4 (9.1)

 

 Little

21 (16.7)

12 (27.3)

0.14

 Moderate

42 (33.3)

12 (27.3)

 

 Good

59 (46.8)

16 (36.4)

 

Family position towards treatment, n (%)

 Negative

0

0

< 0.001

 Neutral

16 (12.7)

18 (40.9)

 

 Supportive

110 (87.3)

26 (59.1)

 
  1. SD standard deviation